Are Late-Stage Deals Beginning to Lose Their Luster?

If there has been anything stable in the pharmaceutical industry, it is an upward trend in late-stage deal prices. And yet, despite the increasing average deal price, the number of big deals is down. In several recent prominent examples, Big Pharma has sharpened its pencils--and said no. The implication: investors will no longer be able to equate late-stage products with blockbuster deals.

If there has been anything stable in the pharmaceutical industry, it is the notion that–with pipelines relatively dry--late-stage deal prices will continue to rise. And statistically, they do. For Phase II and III deals valued at more than $10 million and signed since January 2003, the average up-front fee (including any equity payments) has risen to $43.8 million, compared to about $31.1 million for deals signed in 2002.

And yet, despite the increasing average deal price, the number of big deals is down. "I haven't seen any decrease...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Business Strategy

More from In Vivo